 On May 13, SIOX announced that their AAV9 gene therapy shows beneficial effects in GM1 gangliosidosis, a fatal pediatric genetic disorder. SIOX states that this data represents the first direct evidence in humans that an IV-administered gene therapy exerting a measurable biochemical effect on GM1 ganglioside accumulation within the CNS central-nervous-system. 